The European Medicines Agency has been sued before the European Court for releasing these three documents with extensive redactions due to CCI concerns, which obscure important safety information
However, some of the information in the release is NOT included in the article by Patel, specifically Figure 9. Also note a few admissions from these Pfizer scientists in the second last paragraph.
1. a hidden gene (which Kevin McKernan and others have found)
2. poly (A) tail design ie the segmented poly A tail which may be translated....
For the release for SO1 November 2021, note BioNTech used an engineering run for the analysis. This engineering run, 1071509, is I believe, manufactured in March 2020 and is a Process 1 batch. As a result, the 5' cap and poly A tail quality and quantity will be much different. I also believe the residual DNA in this batch is very high but the dsRNA is very low based on data on the leaked Rolling Review.
This means, that Process 2 batches were not analyzed for the SO1. I am not sure I can prove it conclusively so would like to know if what I have surmised is sufficient from a legal perspective.
Hi Sylvia
Regarding SO1, Pfizer actually PUBLISHED some of these results in a peer reviewed journal.
see here. https://jpharmsci.org/article/S0022-3549(23)00009-6/fulltext
However, some of the information in the release is NOT included in the article by Patel, specifically Figure 9. Also note a few admissions from these Pfizer scientists in the second last paragraph.
1. a hidden gene (which Kevin McKernan and others have found)
2. poly (A) tail design ie the segmented poly A tail which may be translated....
For the release for SO1 November 2021, note BioNTech used an engineering run for the analysis. This engineering run, 1071509, is I believe, manufactured in March 2020 and is a Process 1 batch. As a result, the 5' cap and poly A tail quality and quantity will be much different. I also believe the residual DNA in this batch is very high but the dsRNA is very low based on data on the leaked Rolling Review.
This means, that Process 2 batches were not analyzed for the SO1. I am not sure I can prove it conclusively so would like to know if what I have surmised is sufficient from a legal perspective.
Oligonucleotide Mapping via LC-UV-MS/MS to Enable Comprehensive Primary Structure Characterization of mRNA Drug Substance (by Pfizer) PDF
https://mamconsortium.org/wp-content/uploads/2023/10/2023Sep28_MAMConsortium_OligoMapping_GAUB.pdf
Thank you so much, this is of such high value!
You are welcome, happy to ear it can helps! Let's " lighten" all what they want to hide!